Close

More on ALNY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-6.6% Growth)
- Ratings (6.2 Score)
- Holders
- FDA
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (4/25/24)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

ALNY Income Statement

Click line-items for a historical chart and %
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net revenues from research collaborators 8.71M
Operating expenses:
Research and development 83.17M
General and administrative 17.99M
Total operating expenses 101.16M
Loss from operations -92.45M
Other income (expense):
Equity in loss of joint venture (Regulus Therapeutics Inc.)
Interest income
Other (expense) income 229K
Total other income (expense) 2.32M
Loss before income taxes
Benefit from income taxes
Net loss -90.13M
Net loss per common share - basic and diluted -1.05
Weighted average common shares used to compute basic and diluted net loss per common share
Comprehensive loss:
Net loss -90.13M
Foreign currency translation
Unrealized (loss) gain on marketable securities -18.33M
Comprehensive loss -109.41M
Non-cash stock-based compensation expenses included in operating expenses are as follows:
Research and development
General and administrative